A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

Young-Suk Lim,Sang Hoon Ahn,Kwan Sik Lee,Seung Woon Paik,Youn Jae Lee,Sook Hyang Jeong,Ju Hyun Kim,Seung-Kew Yoon,Hyung-Joon Yim,Won Young Tak,Sang Young Han,Jenny C. Yang,Hongmei Mo,Kimberly L. Garrison,Bing Gao,Steven J. Knox,Phillip S. Pang,Yoon Jun Kim,Kwan Soo Byun,Young Seok Kim,Jeong Heo,Kwang Hyub Han

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

2016

Background The standard-of-care regimen for chronic hepatitis C virus (HCV) infection in Korea, pegylated-interferon-alpha plus ribavirin, is poorly tolerated. Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection.

Keywords:

Hepatitis C virus
Regimen
Virology
European union
Sofosbuvir
Ribavirin
Genotype
Ledipasvir
Fixed-dose combination
Medicine
Virus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations